Design of allele-specific inhibitors to probe protein kinase signaling

Current Biology

Volumn 8, Issue 5, 1998, Pages 257-266

  Bishop, Anthony C ^a   Shah, Kavita ^a   Liu, Yi ^a   Witucki, Laurie ^a   Kung, Chi Yun ^a   Shokat, Kevan M ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032568055     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(98)70198-8     Document Type: Article

References (44)

1. Shokat KM: Tyrosine kinases: modular signaling enzymes with tunable specificities. Chem Biol 1995, 2:509-514.
2. Thomas SM, Soriano P, Imamoto A: Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature 1995, 376:267-271.
3. Bolen JB, Rowley RB, Spana C, Tsygankov AY: The Src family of tyrosine protein kinases in hemopoietic signal transduction. FASEB J 1992, 6:3403-3409.
4. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al.: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995, 377:539-544.
5. Hunter T: A thousand and one protein kinases. Cell 1987, 50:823-829.
6. Norman TC, Gray NS, Koh JT, Schultz PG: A structure-based approach to kinase inhibitors. J Am Chem Soc 1996, 118:7430-7431.
7. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R: Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996, 380:548-550.
8. Groundwater PW, Solomons KRH, Drewe JA, Munawar MA: Protein tyrosine kinase inhibitors. Prog Med Chem 1996, 33:233-329.
9. Levitski A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782-1787.
10. Levitski A: SRC as a target for anti-cancer drugs. Anticancer Drug Des 1996, 11:175-182.
11. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093-1095.
12. Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, et al.: Use of a pharmacaphore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997, 40:3601-3616.
13. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, et al.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995, 92:2558-2562.
14. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, et al.: Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 1997, 40:2296-2303.
15. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, et al.: Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-960.
16. Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N: Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg 1997, 52:88-96.
17. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al.: Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996, 2:561-566.
18. Brown MT, Cooper JA: Regulation, substrates and functions of src. Biochim Biophys Acta 1996, 1287:121-149.
19. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al.: Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. J Biol Chem 1996, 271:695-701.
20. lck. Biochem Biophys Res Commun 1991, 180:1048-1056.
21. fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell 1992, 70:741-750.
22. Hanks SK, Quinn AM: Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 1991, 200:38-62.
23. Shah K, Liu Y, Deirmengian C, Shokat KM: Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci USA 1997, 94:3565-3570.
24. Liu Y, Shah K, Yang F, Witucki L, Shokat K: Engineering src family protein kinases with unnatural nucleotide specificity. Chem Biol 1998, 5:91-101.
25. Sicheri F, Moarefi I, Kuriyan J: Crystal structure of the src family tyrosine kinase hck. Nature 1997, 385:602-609.
26. Xu W, Harrison SC, Eck MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997, 385:595-601.
27. Knighton DR, Zheng JH, Ten-Eyck LF, Ashford VA, Zuong NH, Taylor SS, et al.: Crystal structure of the catalytic subunit of cyclic adenosine monophosphate regulated protein kinase. Science 1991, 253:407-414.
28. Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Zuong N-H, Taylor SS, et al.: Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993, 32:2154-2161.
29. Hardie G, Hanks S: The Protein Kinase Facts Book: Protein-tyrosine Kinases. San Diego: Academic Press Inc; 1995.
30. Jacobson KA, van Galen PJM, Williams M: Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem 1992, 35:407-422.
31. Graziani Y, Erikson E, Erikson RL: The effect of quercetin on the phosphorylation activity of the rous sarcoma virus transforming gene product in vitro and in vivo. Eur J Biochem 1983, 135:583-589.
32. Hanefeld U, Rees CW, White AJP, Williams DJ: One-pot synthesis of tetrasubstituted pyrazoles - proof of regiochemistry. J Chem Soc Perkin Trans 1 1996, 1996:1545-1552.
33. Kobayashi S: The synthesis and xanthine oxidase inhibitory activity of pyrazolo[3,4-d]pyrimidines. Chem Pharm Bull (Tokyo) 1973, 21:941-951.
34. Cambier JC, Jensen WA: The hetero-oligomeric antigen receptor complex and its coupling to cytoplasmic effectors. Curr Opin Genet Dev 1994, 4:55-63.
35. Bishop AC, Moore D, Scanlan TS, Shokat KM: Screening a hydroxystilbene library for selective inhibition of the B cell antigen receptor kinase cascade. Tetrahedron 1997, 53:11995-12004.
36. Morgenstern JP, Land H: Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection marker and a complementary helper-free packaging line. Nucleic Acids Res 1990, 18:3587-3596.
37. Bellagamba C, Hubaishy I, Bjorge JD, Fitzpatrick SL, Fujita DJ, Waisman DM: Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding. J Biol Chem 1997, 272:3195-3199.
38. Martin GS: Rous sarcoma virus: a function required for the transformed state. Nature 1970, 227:1021-1023.
39. Jakobovits EB, Majors JE, Varmus HE: Hormonal regulation of the rous sarcoma virus src gene via a heterologous promoter defines a threshold dose for cellular transformation. Cell 1984, 38:757-765.
40. Kwon HJ, Yoshida M, Fukui Y, Horinouchi S, Beppu T: Potent and specific inhibition of p60 v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res 1992, 52:6926-6930.
41. Whitesell L, Shifrin SD, Schwab G, Neckers LM: Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992, 52:1721-1728.
42. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP: Crystal structure of an hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
43. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994, 91:8324-8328.
44. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N: Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 1995, 270:16580-16587.